Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The Proposed Usage of Intranasal Steroids and Antihistamines for Otitis Media with Effusion

Abstract

Purpose of Review

To examine the role of allergy medications in the treatment of otitis media with effusion (OME), focusing on use of intranasal steroids and antihistamines.

Recent Findings

There has been ongoing controversy regarding the role of allergy in the development of OME. Treatment of OME with medications commonly used for allergic symptomatology has been studied. Proposed treatment options include decongestants, mucolytics, oral steroids, topical steroids, antihistamines, and antibiotics. We begin by evaluating the proposed association between allergy and OME, and then evaluate intranasal steroids and oral antihistamine therapy in the treatment of OME. The role of the adenoid and concurrent nasal symptomatology is also addressed.

Summary

The preponderance of data suggests that neither intranasal steroids nor antihistamines improve the long-term clearance of isolated OME and are therefore not recommended. However, data are notably limited with regard to improvement rates in OME in patients specifically with concurrent allergy and/or adenoid hypertrophy. Future studies of medications for OME would ideally incorporate study designs controlling for both allergic rhinitis and adenoid hypertrophy, to better understand the impact of these medications on OME in these subgroups of patients.

This is a preview of subscription content, log in to check access.

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. 1.

    Allergies | Gateway to Health Communication | CDC. https://www.cdc.gov/healthcommunication/ToolsTemplates/EntertainmentEd/Tips/Allergies.html. Accessed 30 Jul 2018.

  2. 2.

    Blaiss MS. Allergic rhinitis: direct and indirect costs. Allergy Asthma Proc. 2010;31:375–80.

  3. 3.

    Meltzer EO, Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol. 2011;106:S12–6.

  4. 4.

    •• Rosenfeld RM, Shin JJ, Schwartz SR, et al. Clinical practice guideline: otitis media with effusion (update). Otolaryngology–Head Neck Surg. 2016;154:S1–S41 COMMENT: excellent overview of most recent clinical practice guidelines for OME.

  5. 5.

    Vila PM, Thomas T, Liu C, Poe D, Shin JJ. The burden and epidemiology of Eustachian tube dysfunction in adults. Otolaryngol Head Neck Surg. 2017;156:278–84.

  6. 6.

    •• Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: allergic rhinitis: ICAR: allergic rhinitis. Int Forum of Allergy Rhinol. 2018;8:108–352 COMMENT: excellent overview of clinical practice guidelines for allergic rhinitis and its treatment.

  7. 7.

    Goodrich T, Rubio F, Cutler JL. Otitis media and antihistamines. Curr Allergy Asthma Rep. 2009;9:456–9.

  8. 8.

    Rosenfeld RM, Shin JJ. Clinical Practice Guideline. Head Neck Surg 14.

  9. 9.

    Tos M. Epidemiology and natural history of secretory otitis. Am J Otol. 1984;5:459–62.

  10. 10.

    Marom T, Tan A, Wilkinson GS, Pierson KS, Freeman JL, Chonmaitree T. Trends in otitis media–related health care use in the United States, 2001-2011. JAMA Pediatr. 2014;168:68.

  11. 11.

    Finkelstein Y, Ophir D, Talmi YP, Shabtai A, Strauss M, Zohar Y. Adult-onset otitis media with effusion. Arch Otolaryngol Head Neck Surg. 1994;120:517–27.

  12. 12.

    Simpson SA, Lewis R, van der Voort J, Butler CC. Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children. Cochrane Database Syst Rev. 2011:CD001935.

  13. 13.

    Griffin G, Flynn CA. Antihistamines and/or decongestants for otitis media with effusion (OME) in children. Cochrane Database Syst Rev. 2011. https://doi.org/10.1002/14651858.CD003423.pub3.

  14. 14.

    Bousquet J, Annesi-Maesano I, Carat F, Léger D, Rugina M, Pribil C, et al. Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group. Clin Exp Allergy. 2005;35:728–32.

  15. 15.

    Vandenplas O, Vinnikov D, Blanc PD, et al. Impact of rhinitis on work productivity: a systematic review. J Allergy Clin Immunol Pract. 2018;6:1274–1286.e9.

  16. 16.

    Lewis ER. Otitis media and allergy. Ann Otol Rhin Laryng. 1929;38.

  17. 17.

    Krouse JH. The unified airway—conceptual framework. Otolaryngol Clin N Am. 2008;41:257–66.

  18. 18.

    Handelman CS, Osborne G. Growth of the nasopharynx and adenoid development from one to eighteen years. Angle Orthodontist. 1976;46:243–59.

  19. 19.

    Rout MR, Mohanty D, Vijaylaxmi Y, Bobba K, Metta C. Adenoid hypertrophy in adults: a case series. Indian J Otolaryngol Head Neck Surg. 2013;65:269–74.

  20. 20.

    Yazici H, Soy FK, Kulduk E, Doğan S, Dündar R, Sakarya EU, et al. Comparison of nasal mucociliary clearance in adenoid hypertrophy with or without otitis media with effusion. Int J Pediatr Otorhinolaryngol. 2014;78:1143–6.

  21. 21.

    Arnaoutakis D, Collins WO. Correlation of mucociliary clearance and symptomatology before and after adenoidectomy in children. Int J Pediatr Otorhinolaryngol. 2011;75:1318–21.

  22. 22.

    Quaranta N, Milella C, Iannuzzi L, Gelardi M. A study of the role of different forms of chronic rhinitis in the development of otitis media with effusion in children affected by adenoid hypertrophy. Int J Pediatr Otorhinolaryngol. 2013;77:1980–3.

  23. 23.

    Collins MP, Church MK, Bakhshi KN, Osborne J. Adenoid histamine and its possible relationship to secretory otitis media. J Laryngol Otol. 1985;99:685–91.

  24. 24.

    Ulualp SO, Sahin D, Yilmaz N, Anadol V, Peker O, Gursan O. Increased adenoid mast cells in patients with otitis media with effusion. Int J Pediatr Otorhinolaryngol. 1999;49:107–14.

  25. 25.

    Yilmaz HB, Celebi S, Sahin-Yilmaz A, Oysu C. The role of mometasone furoate nasal spray in the treatment of adenoidal hypertrophy in the adolescents: a prospective, randomized, cross-over study. Eur Arch Otorhinolaryngol. 2013;270:2657–61.

  26. 26.

    Bhargava R, Chakravarti A. Role of mometasone furoate aqueous nasal spray for management of adenoidal hypertrophy in children. J Laryngol Otol. 2014;128:1060–6.

  27. 27.

    Bhargava R, Chakravarti A. A double-blind randomized placebo-controlled trial of topical intranasal mometasone furoate nasal spray in children of adenoidal hypertrophy with otitis media with effusion. Am J Otolaryngol. 2014;35:766–70.

  28. 28.

    Butler CC, Van Der Voort JH. Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children. Cochrane Database Syst Rev. 2002:CD001935.

  29. 29.

    Simon F, Haggard M, Rosenfeld RM, Jia H, Peer S, Calmels M-N, et al. International consensus (ICON) on management of otitis media with effusion in children. Eur Ann Otorhinolaryngol Head Neck Dis. 2018;135:S33–9.

  30. 30.

    Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis. 1993;148:S1–26.

  31. 31.

    Howland WC, Hampel FC, Martin BG, Ratner PH, van Bavel JH, Field EA. The efficacy of fluticasone propionate aqueous nasal spray for allergic rhinitis and its relationship to topical effects. Clin Ther. 1996;18:1106–17.

  32. 32.

    Rudmik L, Hoy M, Schlosser RJ, Harvey RJ, Welch KC, Lund V, et al. Topical therapies in the management of chronic rhinosinusitis: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2013;3:281–98.

  33. 33.

    Zitt M, Kosoglou T, Hubbell J. Mometasone furoate nasal spray: a review of safety and systemic effects. Drug Saf. 2007;30:317–26.

  34. 34.

    Tracy JM, Demain JG, Hoffman KM, Goetz DW. Intranasal beclomethasone as an adjunct to treatment of chronic middle ear effusion. Ann Allergy Asthma Immunol. 1998;80:198–206.

  35. 35.

    Lack G, Caulfield H, Penagos M. The link between otitis media with effusion and allergy: a potential role for intranasal corticosteroids: OME and allergy. Pediatr Allergy Immunol. 2011;22:258–66.

  36. 36.

    El-Anwar M, Nofal A, Khazbak A, Sayed A, Hassan M. The efficacy of nasal steroids in treatment of otitis media with effusion: a comparative study. Int Arch Otorhinolaryngol. 2015;19:298–301.

  37. 37.

    Cengel S, Akyol MU. The role of topical nasal steroids in the treatment of children with otitis media with effusion and/or adenoid hypertrophy. Int J Pediatr Otorhinolaryngol. 2006;70:639–45.

  38. 38.

    Akyol MU, Cengel S (2006) The role of topical nasal steroid aerosol treatment in children with otitis media with effusion and/or adenoid hypertrophy. 12 months follow up.

  39. 39.

    •• Cheng X, Sheng H, Ma R, et al. Allergic rhinitis and allergy are risk factors for otitis media with effusion: a meta-analysis. Allergol Immunopathol. 2017;45:25–32 COMMENT: meta-analysis reviewing the relationship between allergic rhinitis and OME.

  40. 40.

    Mikals SJ, Brigger MT. Adenoidectomy as an adjuvant to primary tympanostomy tube placement: a systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg. 2014;140:95–101.

  41. 41.

    van den Aardweg MT, Schilder AG, Herkert E, Boonacker CW, Rovers MM. Adenoidectomy for otitis media in children. Cochrane Database Syst Rev. 2010:CD007810.

  42. 42.

    van den Aardweg MT, Schilder AG, Herkert E, Boonacker CW, Rovers MM. Adenoidectomy for recurrent or chronic nasal symptoms in children. Cochrane Database Syst Rev. 2010:CD008282.

  43. 43.

    Williamson I, Benge S, Barton S, Petrou S, Letley L, Fasey N, et al. A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care. Health Technol Assess. 2009;13:1–144.

  44. 44.

    Williamson I. Otitis media with effusion in children. BMJ Clin Evid. 2011;2011.

  45. 45.

    Petrou S, Dakin H, Abangma G, Benge S, Williamson I. Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial. Value Health. 2010;13:543–51.

  46. 46.

    Gluth MB, McDonald DR, Weaver AL, Bauch CD, Beatty CW, Orvidas LJ. Management of eustachian tube dysfunction with nasal steroid spray: a prospective, randomized, placebo-controlled trial. Arch Otolaryngol Head Neck Surg. 2011;137:449–55.

  47. 47.

    Berkman ND, Wallace IF, Steiner MJ, Harrison M, Greenblatt AM, Lohr KN, et al. Otitis media with effusion: comparative effectiveness of treatments. Rockville: Agency for Healthcare Research and Quality (US); 2013.

  48. 48.

    Newman SP, Morén F, Clarke SW. Deposition pattern from a nasal pump spray. Rhinology. 1987;25:77–82.

  49. 49.

    Thomas WW, Harvey RJ, Rudmik L, Hwang PH, Schlosser RJ. Distribution of topical agents to the paranasal sinuses: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2013;3:691–703.

  50. 50.

    Kanowitz SJ, Batra PS, Citardi MJ. Topical budesonide via mucosal atomization device in refractory postoperative chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2008;139:131–6.

  51. 51.

    Djupesland PG, Skretting A, Winderen M, Holand T. Breath actuated device improves delivery to target sites beyond the nasal valve. Laryngoscope. 2006;116:466–72.

  52. 52.

    Cutler JL, Labadie RF. Effects of ototopical antihistamine on otitis media in an allergic rat. Laryngoscope. 2008;118:283–7.

  53. 53.

    Chonmaitree T, Saeed K, Uchida T, Heikkinen T, Baldwin CD, Freeman DH, et al. A randomized, placebo-controlled trial of the effect of antihistamine or corticosteroid treatment in acute otitis media. J Pediatr. 2003;143:377–85.

  54. 54.

    Coleman C, Moore M. Decongestants and antihistamines for acute otitis media in children. Cochrane Database Syst Rev. 2008:CD001727.

  55. 55.

    Ting S, Rauls DO, Reiman BE. Inhibitory effect of hydroxyzine on antigen-induced histamine release in vivo. J Allergy Clin Immunol. 1985;75:63–6.

  56. 56.

    Suzuki M, Kerakawauchi H, Kawauchi H, Mogi G. Efficacy of an antiallergic drug on otitis media with effusion in association with allergic rhinitis. An experimental study. Ann Otol Rhinol Laryngol. 1999;108:554–8.

  57. 57.

    Griffin G, Flynn CA, Bailey RE, Schultz JK. Antihistamines and/or decongestants for otitis media with effusion (OME) in children. Cochrane Database Syst Rev. 2006. https://doi.org/10.1002/14651858.CD003423.pub2.

  58. 58.

    Mb AGB, Frcpc RDG Antihistamines for children with otitis media. 3.

  59. 59.

    Ertugay CK, Cingi C, Yaz A, San T, Ulusoy S, Erdogmus N, et al. Effect of combination of montelukast and levocetirizine on otitis media with effusion: a prospective, placebo-controlled trial. Acta Otolaryngol. 2013;133:1266–72.

  60. 60.

    Harmes KM, Blackwood RA, Burrows HL, Cooke JM, Harrison RV, Passamani PP. Otitis media: diagnosis and treatment. Am Fam Physician. 2013;88:435–40.

  61. 61.

    •• Wang DE, Lam DJ, Bellmunt AM, Rosenfeld RM, Ikeda AK, Shin JJ. Intranasal steroid use for otitis media with effusion: ongoing opportunities for quality improvement. Otolaryngology-Head Neck Surg. 2017;157:289–96 COMMENT: Study showing that despite randomized controlled trials showing lack of efficacy of intranasal steroids for treatment of OME, this treatment strategy is still commonly used in the US.

  62. 62.

    Prince AA, Rosenfeld RM, Shin JJ. Antihistamine use for otitis media with effusion: ongoing opportunities for quality improvement. Otolaryngol Head Neck Surg. 2015;153:935–42.

  63. 63.

    •• Roditi RE, Rosenfeld RM, Shin JJ. Otitis media with effusion: our national practice. Otolaryngol Head Neck Surg. 2017;157:171–2 COMMENT: Overview of adherence to guidelines for treatment of OME identifying current practice patterns and opportunities for improvement.

  64. 64.

    •• McCoul ED, Weinreich HM, Mulder H, Man L-X, Schulz K, Shin JJ. Health care utilization and prescribing patterns for adult Eustachian tube dysfunction. Otolaryngology–Head Neck Surg. 2019:019459981982695 COMMENT: Study evaluating practice patterns and epidemiologic data in the treatment of eustachian tube dysfunction in adults.

Download references

Author information

Correspondence to Jennifer J. Shin.

Ethics declarations

Conflict of Interest

RER is a consultant for Roche Genentech, Gossamer Bio, and Syneos Health. DSC has no disclosures. JJS receives textbook royalties from Evidence-Based Otolaryngology, Shin JJ, Randolph GW, editors; New York: Springer, 2008, and from Otolaryngology Prep and Practice. Shin JJ, Cunningham MJ, editors; Plural Publishing, 2013. JJS is also a recipient of the American Academy of the Otolaryngology-Head and Neck Surgery Foundation Maureen Hannley grant, the Brigham Care Redesign Program Award, and the Schlager Family Innovations Fund Award.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Otitis

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Roditi, R.E., Caradonna, D.S. & Shin, J.J. The Proposed Usage of Intranasal Steroids and Antihistamines for Otitis Media with Effusion. Curr Allergy Asthma Rep 19, 47 (2019). https://doi.org/10.1007/s11882-019-0879-x

Download citation

Keywords

  • Otitis media with effusion
  • Eustachian tube dysfunction
  • Allergic rhinitis
  • Antihistamines
  • Intranasal steroids
  • Adenoid